Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price & News

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares.
View SPPI analyst ratings or view top-rated stocks.

5 brokerages have issued 1 year price targets for Spectrum Pharmaceuticals' shares. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they predict the company's stock price to reach $2.44 in the next twelve months. This suggests a possible upside of 127.8% from the stock's current price.
View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts.

Spectrum Pharmaceuticals' stock was trading at $0.3685 at the beginning of 2023. Since then, SPPI stock has increased by 190.4% and is now trading at $1.07.
View the best growth stocks for 2023 here.

Spectrum Pharmaceuticals saw a drop in short interest in May. As of May 15th, there was short interest totaling 3,080,000 shares, a drop of 49.2% from the April 30th total of 6,060,000 shares. Based on an average daily volume of 2,290,000 shares, the days-to-cover ratio is presently 1.3 days.
View Spectrum Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our SPPI earnings forecast.

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) released its quarterly earnings data on Wednesday, March, 22nd. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.03. The biotechnology company earned $10.11 million during the quarter, compared to analysts' expectations of $9.60 million.

2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE).

Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."

Spectrum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (8.14%), Acadian Asset Management LLC (1.81%), BlackRock Inc. (1.68%), Geode Capital Management LLC (0.86%), Sargent Investment Group LLC (0.54%) and Renaissance Technologies LLC (0.47%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton.
View institutional ownership trends.

Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SPPI stock can currently be purchased for approximately $1.07.

Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $219.63 million and generates $25.73 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

The company employs 163 workers across the globe.

Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (617) 586-3900, via email at ir@sppirx.com, or via fax at 702-260-7405.